ERBB2 and prostate carcinoma: It was found to be cytotoxic to human rectal cancer cells (HRT-18), androgen-dependent prostate cancer cells (LNcaP), androgen-independent prostate cancer cells (PC-3), HER2-overexpressing breast cancer cells (SKBR3), mouse mammary carcinoma cells (4T1), and mouse melanoma cells (B16F-10) [14].